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The aim of this study is to evaluate epidermal growth factor receptor variant III, EGFRvIII, a
cancer specific mutant, as a possible marker for the diagnosis of breast cancer occult sys-
temic disease. EGFRvIII mRNAwas identified by an RT-nested PCR with a high sensitivity. In
102 women studied, the mutant was detected in the peripheral blood of 30% of 33 low risk,
early stage patients, in 56% of 18 patients selected for neoadjuvant chemotherapy, in 63.6%
of 11 patients with disseminated disease and 0% of 40 control women. In low risk, early
stage patients, the presence of one or more tumour characteristics predicting recurrence
such as the absence of oestrogen receptors and the presence of ERBB2 or histologic grades
G2/G3 was significantly associated with EFGRvIII detection (p < 0.05). EGFRvIII mRNA has
characteristics to be a useful marker for the diagnosis of occult systemic disease in breast
cancer. Follow-up studies will evaluate its clinical value as a decision criterion for systemic
therapy.
 2006 Elsevier Ltd. All rights reserved.1. Introduction
Breast cancer is the second leading cause of death by cancer
in most Western countries. Prognosis is mainly dependent
on the extension of the disease, but even with themost recent
medical advances, 20–30% of patients with an apparently
localised cancer will relapse. The most likely reason is an
early, occult systemic dissemination.
The diagnosis of occult systemic disease may constitute a
significant improvement in the treatment and prognosis of
breast cancer.1–3 It may help to improve staging, especially
in patients with apparently localised disease, to monitor the
effectiveness of therapy and to allow a pre-clinical diagnosis
of recurrences in patients already in follow-up.
PCR methodologies have been widely used in the detection
of occult systemic disease in blood and bone marrow of can-er Ltd. All rights reserved
; fax: +351 239 823236.
. Silva).cer patients. However, no suitable marker is available.
Tumours are very heterogeneous and may express different
mRNAs and proteins. Unfortunately, the most frequently
and highly expressed markers are not cancer specific and
false positives from illegitimate transcription are common
in PCR-based technologies. Therefore, the search for specific
markers remains an important issue to pursue.
Epidermal growth factor receptor variant III (EGFRvIII) is the
most common mutant of EGFR, a receptor described in all cell
types with the exception of haematopoietic cells. The mutant
results from an in-frame deletion of the coding exons 2–7, cor-
responding to a deletion of 801 bp from themRNA.4–6 The rear-
rangement creates a new peptide sequence at the extra-
cellular domain, with a new amino acid, glycine, at the fusion
junction. EGFRvIII may result from genomic deletion associ-
ated with EGFR amplification, or from alternative splicing.7–9.
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receptor.8,10 Its expression has been detected in a wide variety
of humanmalignancies, including up to 50–78% of breast can-
cers.8,11–13 No detectable level of protein or mRNA of EGFRvIII
has, however, been observed in normal adult tissues, including
normal breast tissues.7,11,14 There is compelling evidence that
the expression of EGFRvIII enhances tumourigenicity10,15,16
and invasiveness10,16,17 and is associated with chemo and
radioresistance.18,19 Efforts are being developed to delineate
cancer specific therapies having EGFRvIII as a target.20,21
In this work, EGFRvIII mRNA is evaluated as a possible
marker for the diagnosis of breast cancer occult systemic
disease.
2. Materials and methods
2.1. Cell lines
U87MGDEGFR, a glioblastoma cell line expressing EGFRvIII
and not EGFR, was generously provided by Professor Wong
from the Ludwig Institute for Cancer Research (La Jolla, San
Diego); it was maintained in DMEM supplemented with 10%
FBS and 200 lg/ml of Geneticin. CTLL-2, a lymphoblastic cell
line, was a generous gift from the Histocompatibility Centre
of Coimbra; cells were cultured in RPMI containing 2 mM of
L-glutamine, 10% FBS, 10 U/ml of IL-2, 1 mM of pyruvate and
1% penicillin–streptomycin. MDA-MB-231, a breast carcinoma
cell line expressing only EGFR, was acquired from ATCC and
maintained following the instructions.Table 1 – Characteristics and results of the different
groups
Population
characteristics
Total
population
EGFRvIII
positives
Group A
(Age: mean – 63.6 ± 11.3)
T2N0 9 3
T1N0 24 7
Total 33 10 (30%)a
Group B
(Age: mean – 48 ± 12.59)
IIAb 4 2
IIBb 3 2
IIIAb 4 3
IIIBb 7 3
Total 18 10 (56%)a
Group C (stage IV)b
(Age: mean – 56.7 ± 17.6)
Bone metastasis 6 4
Multiple sitesc 4 3
Otherd 1 0
Total 11 7 (63.6%)a
Group D
(Age: mean – 41.3 ± 11.4)
Total 40 0
a p > 0.05 (Yates’ p value).
b FIGO classification.
c With bone and visceral metastasis.
d Supra-clavicular lymph node metastases.2.2. Patients
One hundred and two women divided into four groups were
studied: group A, with 33 T1N0M0 or T2N0M0 (TMN, clinical
classification) breast cancer patients, with a mean age of
63.6 ± 11.3 and with tumours of 3 cm or less of diameter, se-
lected for curative surgery; group B with 18 high risk patients,
with amean age of 48 ± 12.6, selected for neoadjuvant chemo-
therapy; group C, with 11 patients with disseminated disease,
with a mean age of 56.7 ± 17.6 and group D, a control group of
40 women free of any type of cancer with a mean age of
41.3 ± 11.4 (Table 1). Group B is heterogeneous and includes
women from stage II A to stage III B (FIGO classification), as
described in Table 1. In group A, blood was collected before
surgery and in groups B and C before chemotherapy. Blood
samples were processed within 1 h of collection. All patients
had carcinomas of ductal invasive histological type, except
one with an intraductal carcinoma with microinvasion and
another with an invasive tumour with ductal and lobular dif-
ferentiation. Patients were undergoing treatment in the
Gynaecological Department of Coimbra University Hospital.
Samples were consecutively collected during the period of 1
year according to patient consent and sample quality de-
mands. Ethical approval was obtained from the Hospital Eth-
ical Committee and all subjects gave their informed consent.
Group D included University and Hospital staff, with a medi-
cal consultation during the last year, and women attending
the Gynaecological Department for benign disorders.
2.3. Patient samples
Twenty-three tumour samples were collected from breast
cancer patients submitted to surgery in the Gynaecological
Department, 18 of which were from the group A patients.
All these samples were of ductal invasive histological type.
Samples were collected and immersed in RNAlater (Qiagen)
within 1 h after surgery and kept at 20 C or 80 C until
RNA extraction.
The mononuclear cell fraction of 10 ml of EDTA treated
blood was separated by gradient density centrifugation with
Ficoll. A total of 5 · 106–1 · 107 viable cells were used for
RNA extraction.
2.4. RNA extraction and RT-PCR
Total RNA was extracted from cell lines with the ‘Rneasy Kit’
(Quiagen), and from blood and tissues with the ‘Ultrasepc
RNA isolation Kit’ (Biotecx) according to the manufacturer’s
instructions. RNA was quantified spectrophotometrically at
260 nm and stored at 80 C. Synthesis of cDNA was per-
formed with ‘Omniscript kit’ (Quiagen), according to the sup-
plied protocol, using random hexamers (Pd(N)6) and 5 lg of
total RNA.
The quality of synthesis was verified by amplifying a se-
quence of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) cDNA (GenBank BC029618). A 171 bp sequence was
amplified using primers 5 0-TCG CCA GCC GAG CCA CAT CG-
3 0 (forward) and 5 0-GAA CAT GTA AAC CAT GTA G-3 0 (reverse).
PCR was accomplished with 2 ll of cDNA, and 35 cycles with
56 C of annealing temperature. Reaction products (7.5 ll)
E U R O P E A N J O U R N A L O F C A N C E R 4 2 ( 2 0 0 6 ) 2 6 1 7 –2 6 2 2 2619were electrophoresed on a 2% agarose gel stained with ethi-
dium bromide.
Nested PCR was designed adapting conditions already de-
scribed.11,22 In both PCRs, we used Taq DNA polymerase Kit
with Q-solution (Quiagen) and dUTP in substitution for dTTP.
In the first round PCR, the forward primer was 5 0-GTA TTG
ATC GGG AGA GCC G-3 0 and the reverse primer was 5 0-GTG
GAG ATC GCC ACT GAT G-3 0. PCR was performed with a
50 ll reaction mixture containing 5–8 ll of cDNA, buffer 1·,
Q-solution 1·, 200 lM of dNTPs (dATP, dGTP, and dCTP),
600 lM of dUTP, 0.5 lM of each primer, 2.5 mM of MgCl2, 3 U
of Taq DNA polymerase and 1 U of N-uracyl glycosylase
(UNG) heat labile. Samples were maintained for 5 min at
25 C for UNG reaction and then kept for 2 min at 95 C for
UNG inactivation. PCR consisted in 40 cycles in the following
conditions: 95 C for 45 s, 60 C for 45 s and 72 C for 90 s. PCR
samples were then preserved at 4 C. For the second PCR, 1–
5 ll of the first PCR was used. The forward primer was 5 0-
GCG ATG CGA CCC TCC GGG-3 0 and the reverse primer was
5 0-TCC GTT ACA CAC TTT GCG-3 0. Master mix composition
was the same except for UNG. For amplification, one cycle
of 94 C for 2 min was followed by 35 cycles of 45 s at 95 C,
1 min at 55 C and 1 min at 72 C. 8 ll of cDNA and 5 ll of
the first PCR were used in the higher RNA dilutions in sensi-
tivity assays (1/105–1/108) and with patients and control blood
samples.
For EGFRvIII, the first PCR amplifies a sequence of 352 bp
and the second PCR amplifies a sequence of 219 bp (GenBank
NM_201283). For EGFR, the sequences amplified in the first
and second PCR are 801 bp longer. Reaction products (15 ll)
from the first and second PCRs were resolved on a 1.5% aga-
rose gel stained with ethidium bromide.
In each set of RT-PCRs, the desired sensitivity was con-
firmed using dilutions (1/104–1/107) of total RNA from EGFRvIII
expressing cell line in total RNA from CTLL-2 cell line, as de-
scribed in the sensitivity tests. Patients’ samples were tested
in triplicate and dilution samples in duplicate. Whenever
both 1/107 dilutions were negative, the sensitivity of the assay
was considered to be insufficient and PCRs were repeated. At
least two negative water blanks were included in each reac-
tion. One of the negative water blanks of each reaction was
used in the following procedures, from the cDNA to the sec-
ond PCR, to assure the absence of contamination. In the first
and second PCRs, the samples used to test the sensitivity
were the last to be handled, from the higher to lower dilution,
ending with the negative water blanks. Tissue processing,
RNA extraction, RT-PCR assay set-up and post-PCR product
analysis were performed in separate rooms to avoid
contamination.
Sensitivity was established by serially diluting total RNA
from U87MGDEGFR or from MDA-MB-231 cell lines into 5 lg
of total RNA extracted from CTLL-2 cell line. Serial dilutions
were also done with a mixture of equal quantities of RNAs
from EGFRvIII and EGFR expressing cell lines into 5 lg of total
RNA from CTLL-2 cell-line. Dilutions ranged from 1/10 to
1/108.
The specificity of the RT-PCR products was confirmed by
DNA sequencing the products of the second PCR obtained
from expressing cell lines and from some random selected
positive blood and tumour samples. The specificity was alsoconfirmed by applying the same RT-nested PCR assay to cells
that do not express EGFRvIII: MDA-MB-231 and CTLL-2 cell
lines and normal nucleated blood cells.
The protocol assures that only mRNA is amplified: for
EGFR, the DNA sequences corresponding to the product
amplified by the RT-PCR include several introns; for EGFRvIII,
the reverse primer of the second PCR spans exons 8 and 9
junction.
2.5. Statistical analysis
Student’s t test for continuous variables and Yates’ v2 test for
categorical variables were used. A p-value <0.05 was consid-
ered statistically significant.
3. Results
As described in the last section, the sensitivity results con-
cern RNA dilutions. For EGFRvIII marker, a sensitivity of 1/
104 was achieved in the first PCR. With nested PCR the sensi-
tivity was of 1/107. For EGFR, the first PCR had a sensitivity of
1/103 and the nested PCR a sensitivity of 1/106 (Fig. 1a). When
both markers were simultaneously used, for higher dilutions
(1/105–1/107), only the deleted form was detected, achieving
the same sensitivity of 1/107 (Fig. 1b). Dilutions with eight po-
sitive results out of ten were considered to be within the sen-
sitivity threshold. For 1/108 dilutions, only two in ten samples
were positive, so this dilution was considered to be above the
sensitivity of the assay.
Confirming the specificity of the assay and of the markers,
EGFRvIII mRNA was only identified from U87MGDEGFRF cell
line and not from MDA-MB-231 or CTLL-2 cell lines or normal
leukocytes. EGFR mRNA was also identified only in MDA-MB-
231 cell line.
As shown in Table 1, in group D, of control women, there
were no positive cases for EGFR or EGFRvIII. In the patient
population, in group A, 10 were EGFRvIII positive (30%); in
group B, 10 (56%) were EGFRvIII positive and in the metastatic
group, 7 (63.6%) were also EGFRvIII positive (Yates’ p value
>0.05). The positive results were only seen with the nested
PCR and not in the first PCR, even in blood samples frommet-
astatic patients (Fig. 1c). Patients’ samples were done in trip-
licate and all positive results were positive at least twice.
For group A, some risk factors of tumour recurrence were
analysed between EGFRvIII positive or negative patients in
peripheral blood (Table 2). There was no significant difference
for age, microscopic diagnosed lymph node metastasis or tu-
mour size. For other biological markers associated with tu-
mour relapse, such as absence of oestrogen receptors (ER),
G2–G3 histologic grade and expression of ERBB2, there was a
clear higher incidence in patients EGFRvIII-positive in periph-
eral blood, reaching a statistically significant difference
(p < 0.05) when the presence of one or more of these factors
was considered.
To confirm the high frequency of breast cancers positive
for EGFRvIII mRNA described in the literature, a group of 23
breast cancer samples, 18 of which belonging to group A of
patients, was studied. In other patients from group A, it was
not possible to collect tissue samples mostly due to the re-
duced dimensions of the tumours. Results showed that
a       N     10-4 10-5 10-5 10-6  10-6 φX b 10-5 10-5 10-6 10-6 10-7 10-710-810-8  N φX   P
c 1     N    3    4     P    6    7     8    9    10 φX d         N    2    3     4    5     6    7     8    P1   P2 φX
Fig. 1 – (a) Sensitivity of nested RT-PCR for EGFR: N, negative control with RNA from CTLL-2 cell line; 104–106 – serial
dilutions of RNA from EGFR-expressing cell line in RNA from the non-expressing cell line, CTLL-2; uX  uX 174-HaeIII DNA
ladder. (b) Sensitivity of nested RT-PCR for both EGFR and EGFRvIII: 105–108 serial dilutions of RNAs from both EGFR and
EGFRvIII-expressing cell lines in RNA from the non-expressing cell line; N, negative, water-blank control; uX  uX 174-HaeIII
DNA ladder; P, EGFRvIII-expressing cell line. In these higher dilutions, the sequence of EGFRvIII is preferentially amplified. (c)
Results of the nested RT-PCR of patients blood samples: N, negative water-blank control; lanes 3 and 10 are negative results; P,
EGFRvIII expressing cell-line; uX  uX 174-HaeIII DNA ladder. (d) Results of the nested RT-PCR of tumour samples: N, negative
water-blank control, lanes 2–8, tumour samples; P1, EGFR expressing cell line; P2, EGFRvIII expressing cell line; uX  uX 174-
HaeIII DNA ladder. The lower band seen in (c) and (d) corresponds to excess of primers and is only apparent when
amplification is absent or minimum.
Table 2 – Recurrence predictive factors in group A patients
Age Tumour
size P2 cm
pN1 ER negative Grade
G2–G3
ERBB2
positive
ER-/G2-G3/ERBB2+
P1* P2*
EGFRvIII positive, N = 10 58.9 ± 11.4 3/10 (30%) 1/10 (10%) 3/10 (30%) 9/10 (90%) 5/10 (50%) 10–10* (100%) 7/10 (70%)
EGFRvIII negative, N = 10 64.6 ± 11.2 6/23 (26%) 4/23 (17.4%) 3/23 (13%) 12/23 (52%) 9/23 (39%) 13/23* (56.5%) 9/23 (43.55%)
Statistic: Student’s-t test for age and v2 test for other variables; *p < 0.05 for the presence of at least one of the factors; pN1, lymphatic node
microscopic metastases; ER, for absence of oestrogen receptor; ERBB2+ for presence of this receptor.
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65% being positive for EGFRvIII in nested PCR (Fig. 1D). Of the
10 group A patients with EGFRvIII identified in the peripheral
blood, only three had the tumour studied: two samples were
positive for the mutant and one for both the mutant and
the normal transcript.
4. Discussion
In this paper, EGFRvIII mRNA is evaluated as a possible mar-
ker for the diagnosis of breast cancer occult systemic disease.
Characterisation of tumour samples confirmed the high fre-
quency of the mutant in breast cancer: 82.6% of the tumours
were positive for EGFRvIII and/or EGFR. The RT-nested PCR as-
say achieved a high sensitivity of 1/107 for EGFRvIII and 1/106
for EGFR. The lower sensitivity for EGFR, especially when both
markers were present, was probably due to the longer ampli-
fication sequence, and explains the absence of positive re-
sults. The mutant was never detected in the first PCR, even
in the metastatic group of patients, confirming the need for
a highly sensitive assay. The rate of EGFRvIII positive cases
in patients with advanced cancer was higher than in patients
with clinically localised disease, supporting the usefulness of
this assay. The identification of EGFRvIII mRNA in differentstages of the disease reveals that the mutant expression is
stable during cancer evolution, an important feature for a tu-
mour marker. Also, in the early stage patients, the presence of
one or more tumour characteristics predicting recurrence
such as the absence of oestrogen receptor (ER) and the pres-
ence of ERBB2 or histologic grades G2/G3 was significantly
associated with EFGRvIII positive results in the peripheral
blood (p < 0.05). This is particularly interesting because ERBB2
and G2 histologic grade are not always considered for adju-
vant chemotherapy prescription. Though the number of pa-
tients does not allow definitive conclusions, results suggest
that these two tumour phenotypic characteristics and EGFR-
vIII positive results in peripheral blood might help to identify
those patients with T1N0M0 disease, not submitted to chemo-
therapy, but that still will relapse. Giving that in these early
stage patients, the incidence of recurrences and of blood
detection of markers of occult systemic disease is usually
low, follow-up studies with larger number of patients must
be accomplished to confirm the usefulness of EGFRvIII.
The lack of association between positive results in the
peripheral blood and tumour size or lymph-node involvement
has been described in other studies.1,2 There are evidences
that distinct biological processes support lymph-node and
haematic dissemination.23
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PCR are comparable to those described by other authors in
peripheral blood, using nested PCR,2,3,24 real time PCR25 or re-
cently developed antibody-based assays.26 In sensitivity tests,
for practical purposes, mRNA dilutionswere used, as sensitiv-
ity was tested in every PCR set of blood samples. Though the
dilution of cells from expressing cell lines in blood samples is
certainly a more desirable method, RNA and even cDNA dilu-
tions have often been used.24,26–28 To avoid contamination of
blood samples from cell epidermis some authors proposed to
discard the first millilitres of blood, but recently, this cause of
false positive results was questioned.25 Therefore, and be-
cause the EGFRvIII is a cancer specific marker, we used the
whole blood sample in patients and controls.
EGFR has already been described as a good marker for the
detection of circulating cancer cells in breast cancer pa-
tients,24,26 though false positives may appear because of ille-
gitimate transcription. As a marker, EGFRvIII offers the
advantage of being cancer specific, thus, reducing false
positives.
A double-mutant EGFRvIII, with an additional deletion of
exons 12 and 13, has rarely been described29 andmay be iden-
tified by our protocol. This rare mutant has only been associ-
ated with EGFR positive tumours, so a positive result in
peripheral blood would have the same meaning as an EGFR-
vIII positive result.
As a quantitative value for positive results may be impor-
tant in prognosis evaluation, a real-time PCR with TaqMan
probes for EGFRvIII and EGFR was tried, but the sensitivity
achieved, of 1/104, was insufficient, and, as expected by the
nested-PCR results, no positive cases were detected in blood
samples. In the diagnosis of occult systemic disease, real time
PCR has mostly been used in patients with advanced breast
cancer3,25 and few authors have described sensitivities higher
than 1/105 in this specific application of real-time PCR.25
Although real-time PCR is a highly reproducible quantitative
PCR, contrarily to image-assisted systems, it cannot accu-
rately quantify the number of tumour cells corresponding to
the mRNA levels or evaluate the extension of the disease.25,28
For the diagnosis of occult systemic disease in solid tumours,
this methodology has mainly been used to eliminate the
background signal obtained from almost all markers, by
establishing a cutoff point that distinguishes true positives
from false positives.3,25,28,30
The complexity of metastasis explains its unpredictability
and enhances the need for highly sensitive and specific meth-
odologies enabling the identification of specific markers
implicated in tumourigenesis and metastasis. Unfortunately,
specific markers, like EGFRvIII or mammaglobin31, demand
assays with sensitivities not easily achieved.
Although the expression of EGFRvIII has been described in
50–72% of breast cancers by many authors,8,11–13 using differ-
ent methodologies (PCR, immunohistochemistry andWestern
blotting), including laser capture technology,13 recently the
absence of EGFRvIII expression in breast cancer paraffin-
embedded samples was reported.32 These conflicting results
may be explained by differences in sensitivity assays and in
sample management. So that archived tissues accurately re-
flect mRNA expression before fixation, some factors have to
be optimised, namely time from surgical excision to fixa-tion.33 This is critical when concerning breast cancer sam-
ples, because of the pathological procedures necessary for
staging. Less abundant mRNAsmay be lost. It was also proven
that the process of formalin fixation and paraffin embedding
differentially affects the ability to analyse different mRNA
species even from the same gene.33
Despite the frequent expression of EGFRvIII in human epi-
thelial cancers, it has been difficult to detect EGFRvIII expres-
sion in most human cancer cell lines.18,32 The common
explanation, either a growth disadvantage in vitro or a positive
selection for EGFRvIII in vivo, was recently confirmed by two
different groups.21,34 A similar phenomenon has been verified
with other genes.35
In the diagnosis of breast cancer occult systemic disease, it
is important to search for a panel of specific cancer markers
to create personalised protocols. EGFRvIII has characteristics
to be an interesting candidate, though it requires a highly
sensitive methodology. It has the advantage of being a cancer
exclusive mutation associated with tumourigenicity and
metastasis and of being a good target for specific therapy. In
early stage disease, the detection of EGFRvIII in peripheral
blood is associated with indicators of tumour aggressiveness.
Larger sample studies and long term observation will evalu-
ate its clinical value as a decision criterion for systemic
therapy.
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